Includes Current Assets, Liabilities and Stockholder's Equity
Quarter Ended Jun 30, 2021
Revenue for the three and six months ended June 30, 2021 was $3.1 million and $3.5 million, respectively, compared to $0.5 million and $1.3 million for the same periods in 2020.
As of June 30, 2021, Adaptimmune had cash and cash equivalents of $50.5 million and Total Liquidity1 of $285.4 million.
For Fiscal Year Ending Dec 31, 2020
For complete information regarding our financials, see our periodic filings